.svg?rev=0123a45359b34a45b72f615f84c63d11&hash=D9D267D4F8A003D6A105C987E125D147){kind=logo}
Pharmaceuticals & Biologics
Overview
By bringing innovative products to market, pharmaceutical companies help people live longer, higher-quality lives — and our attorneys and other professionals are dedicated to facilitating that progress. Our professionals include former in-house counsel and senior executives for some of the world’s largest pharmaceutical companies, as well as an interdisciplinary team of experienced attorneys and professionals who provide regulatory, transactional, litigation, intellectual property, and government affairs services tailored to the pharmaceutical industry. We help clients tackle business and financing pressures, regulatory scrutiny, and litigation threats on a national and international scale. We have steered global pharma companies through multibillion-dollar transactions and helped international drug manufacturers accelerate drug development through creative joint ventures. Our IP attorneys work to patent your inventions in countries around the globe; shield your brands through trademark policing and anti-counterfeiting strategies; and negotiate commercial, licensing, and other strategic agreements — freeing you to focus on product development and innovation. We serve as outside general counsel for regulatory compliance matters and support on all interactions with the Food and Drug Administration and other regulatory parties, including inspections, investigations, and enforcement. And when disputes occur, our trial lawyers are there to handle any issue. Whether enforcing your rights or defending against alleged wrongdoing, including in product liability litigation, our team of skilled trial attorneys is ready to represent you in high-stakes, bet-the-company litigation every day.
Insights & Events
Latest
Second Circuit Adopts the Indirect Purchaser Rule for Civil RICO
Priorities of People Living With Alzheimer's and Care Partners: What Matters Most?
Nick Nastasi Comments on 340B Legislative Outlook With Healthcare Financial Management Association
Mollie Sitkowski Discusses CBP’s Guidance on Section 232 Pharma Tariffs in International Trade Today
Mollie Sitkowski Comments on Pharmaceutical Tariff Developments in Endpoints News
Tariffs, Trade Policy, and Supply Chains Under Pressure: Critical Considerations for Life Sciences Companies Operating in High-Stakes International Markets
Libby Baney Burstein Discusses Risks Associated with PBM Cost-Containment Strategies in Modern Healthcare
Florida IP Litigation & Regional Innovation
Trevor Belden and James Strickland Named Indiana Lawyer ‘Leadership in Law’ Honorees
Faegre Drinker Represents Teva Pharmaceutical in its Agreement to Acquire Emalex Biosciences
Insights
Second Circuit Adopts the Indirect Purchaser Rule for Civil RICO
Priorities of People Living With Alzheimer's and Care Partners: What Matters Most?
Nick Nastasi Comments on 340B Legislative Outlook With Healthcare Financial Management Association
Mollie Sitkowski Discusses CBP’s Guidance on Section 232 Pharma Tariffs in International Trade Today
Mollie Sitkowski Comments on Pharmaceutical Tariff Developments in Endpoints News
Libby Baney Burstein Discusses Risks Associated with PBM Cost-Containment Strategies in Modern Healthcare
The Intel Report: Quarterly National Security Briefing — 2026 Q2
HHS Office of Inspector General Declares That Fair-Market-Value Transactions Can Be Kickbacks
FDA-Related Legislative and Regulatory Proposals and Funding Change the President's FY27 Budget
Expert Witness Practice in U.S. Drug and Medical Device Litigation
Events
Past Events
Tariffs, Trade Policy, and Supply Chains Under Pressure: Critical Considerations for Life Sciences Companies Operating in High-Stakes International Markets
Florida IP Litigation & Regional Innovation
AI Policy and the New Administration: Implications for FDA-Regulated Industries
Managed Care, Enforcement and Compliance
Federal and State Enforcement of Private Equity Investment in Health Care
News
Trevor Belden and James Strickland Named Indiana Lawyer ‘Leadership in Law’ Honorees
Faegre Drinker Represents Teva Pharmaceutical in its Agreement to Acquire Emalex Biosciences
Wayne Mason Inducted as Fellow to the International Academy of Trial Lawyers
Jessica Natali Honored With Temple Law’s 2026 Women’s Law Caucus Leadership Award
Faegre Drinker Strengthens Nationwide Product Liability & Mass Torts Practice, Adding Medical Device Litigator Dan Smulian in New York
Faegre Drinker Grows Customs & International Trade Practice in Washington, D.C., Welcoming Prominent Trade Enforcement Partner Daniel Wilson
Faegre Drinker Welcomes Former Senate HELP Committee General Counsel Barrett Tenbarge to Government and Regulatory Group
Faegre Drinker Welcomes Partner Greg Mitchell, Life Sciences Patent Team to Intellectual Property Practice
Faegre Drinker Welcomes Life Sciences Litigator Tom Pack to California Product Liability & Mass Torts Team
Faegre Drinker Announces 2025 Partner Class and New Counsel Promotions
Related Legal Services
Experience
Our Experience
Teva Pharmaceutical Completes Agreement to Acquire Emalex Biosciences
Faegre Drinker Team Secures Favorable Ruling for Regeneron in FCA Kickback Case
Pharmaceutical Company Enforces Trademarks
National Association of Boards of Pharmacy Focuses on Legal and Policy Matters
Merck Animal Health Acquires Virtual Fencing Company Vence Corp
Tyme Technologies Completes Merger With Syros Pharmaceuticals
Meet The Team
Meet The Team
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Terry L. Frangiosa
Principal - Faegre Drinker Consulting -
Timothy R. Franson, M.D.
Principal - Faegre Drinker Consulting -
-
Mary Susan Gerber
Intellectual Property Attorney -
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Ilse Peterson, MPH
Director - Research & Strategy -
-
-
-
-
-
Fatou Hann Sarr
Manager - Research & Policy -
-
-
-
-
-
-
-
-
-
-
-
-
